Asset profile
Finerenone · Kerendia
Small molecule
Evidence outlook
Approved: Chronic Kidney Disease, Heart Failure (label: heart failure with LVEF 40% or more (HFpEF and HFmrEF))
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
111 competitors in this universe: 1 direct rival (same mechanism and indication), 1 same-class, 109 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Finerenone (Kerendia): this drug | Approved | Small molecule | Mineralocorticoid receptor | ||
| Balcinrenone | Phase 3 | Small molecule | Mineralocorticoid receptor | ||
| Esaxerenone (Minnebro) | Phase 3 | Small molecule | Mineralocorticoid receptor | ||
| Atrasentan (Vanrafia) | Approved | Small molecule | Endothelin A receptor | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Budesonide (targeted-Release) (TARPEYO / Nefecon) | Approved | Small molecule | Glucocorticoid receptor | ||
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Daprodustat (Jesduvroq) | Approved | Small molecule | HIF prolyl hydroxylase (HIF-PH1/2/3) | ||
| Difelikefalin (Korsuva) | Approved | Peptide | Kappa-opioid receptor (agonist, peripherally restricted) | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Etelcalcetide (Parsabiv) | Approved | Peptide | Calcium-sensing receptor (CaSR), allosteric agonist on parathyroid chief cells | ||
| Extended-Release Calcifediol (Rayaldee) | Approved | Small molecule | Vitamin D receptor (VDR), via conversion to calcitriol | ||
| Ferric Carboxymaltose (Injectafer / Ferinject) | Approved | Iron Complex (iv) | Iron repletion | ||
| Ferric Derisomaltose (Monoferric / Monofer) | Approved | Iron Complex (iv) | Iron repletion |
…and 96 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(36 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (4)
October 2026 (1)
What to watch
November 2026 (1)
What to watch
2027 (17)
February 2027 (1)
What to watch
March 2027 (2)
April 2027 (3)
What to watch
What to watch
What to watch
May 2027 (1)
What to watch
July 2027 (1)
What to watch
September 2027 (1)
What to watch
October 2027 (4)
What to watch
What to watch
What to watch
What to watch
November 2027 (2)
2028 (6)
January 2028 (1)
What to watch
March 2028 (1)
What to watch
June 2028 (1)
What to watch
August 2028 (2)
December 2028 (1)
What to watch
2029 (7)
January 2029 (1)
What to watch
February 2029 (1)
What to watch
March 2029 (1)
What to watch
July 2029 (1)
What to watch
November 2029 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.